{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:02:28Z","timestamp":1792512148786,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Context<\/jats:title>\n                <jats:p>Pasireotide-LAR, a second-generation somatostatin receptor ligand (SRL), is recommended for patients with acromegaly as second-line treatment. Its efficacy and safety were assessed in clinical trials; however, the real-world evidence is still scarce.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>The aim of this study was to evaluate the impact of 1-year treatment with pasireotide-LAR on disease\u00a0control and glucose metabolism in acromegaly patients\u00a0resistant to first-generation SRLs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Design<\/jats:title>\n                <jats:p>A single-center prospective study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Twenty-eight\u00a0patients with active acromegaly or acrogigantism on first-generation SRLs following ineffective pituitary surgery were switched to treatment with pasireotide-LAR 40 or 60\u00a0mg i.m. every 28\u00a0days. To assess the efficacy of the treatment GH and IGF-1 levels were measured every 3\u00a0months. Safety of treatment was carefully evaluated, especially its impact on glucose metabolism.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Complete biochemical control (GH\u2009\u2264\u20091\u00a0ng\/mL and IGF-1\u2009\u2264\u20091\u2009\u00d7\u2009ULN) was achieved in 26.9% of patients and partial\u2009+\u2009complete response (GH\u2009\u2264\u20092.5\u00a0ng\/mL and IGF-1\u2009\u2264\u20091.3\u2009\u00d7\u2009ULN) in 50.0% of patients. Mean GH level decrease was the largest within first 6\u00a0months (P\u2009=\u20090.0001) and mean IGF-1 level decreased rapidly within the first 3\u00a0months (P\u2009&lt;\u20090.0001) and they remained reduced during the study. Blood glucose and HbA1c levels increased significantly within 3\u00a0months (P\u2009=\u20090.0001) and stayed on stable level thereafter. Otherwise, the treatment was well tolerated and clinical improvement was noticed in majority of patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This real-life study confirmed good effectiveness\u00a0of pasireotide-LAR\u00a0in patients resistant to first-generation SRLs. Pasireotide-LAR was overall safe and\u00a0well tolerated, however significant glucose metabolism worsening was noted.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11102-021-01185-w","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T17:02:48Z","timestamp":1631120568000},"page":"180-190","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2961-3316","authenticated-orcid":false,"given":"Maria","family":"Stelmachowska-Bana\u015b","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabella","family":"Czajka-Oraniec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Tomasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Zgliczy\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,8]]},"reference":[{"issue":"9","key":"1185_CR1","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","volume":"14","author":"S Melmed","year":"2018","unstructured":"Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH et al (2018) A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 14(9):552\u2013561","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"1185_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11102-016-0772-8","volume":"20","author":"L Vilar","year":"2017","unstructured":"Vilar L, Vilar CF, Lyra R, Lyra R, Naves LA (2017) Acromegaly: clinical features at diagnosis. Pituitary 20(1):22\u201332","journal-title":"Pituitary"},{"key":"1185_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/B978-0-444-59602-4.00014-9","volume":"124","author":"P Chanson","year":"2014","unstructured":"Chanson P, Salenave S, Kamenicky P (2014) Acromegaly. Handb Clin Neurol 124:197\u2013219","journal-title":"Handb Clin Neurol"},{"issue":"3","key":"1185_CR4","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1530\/EJE-10-0811","volume":"164","author":"G Mazziotti","year":"2011","unstructured":"Mazziotti G, Porcelli T, Bogazzi F, Bugari G, Cannav\u00f2 S, Colao A et al (2011) Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. Eur J Endocrinol 164(3):341\u2013347","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1185_CR5","first-page":"20","volume":"60","author":"M Stelmachowska-Bana\u015b","year":"2009","unstructured":"Stelmachowska-Bana\u015b M, Zdunowski P, Zgliczy\u0144ski W (2009) Abnormalities in glucose homeostasis in acromegaly. Does the prevalence of glucose intolerance depend on the level of activity of the disease and the duration of the symptoms? Endokrynol Pol 60(1):20\u201324","journal-title":"Endokrynol Pol"},{"key":"1185_CR6","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3389\/fendo.2018.00358","volume":"9","author":"F Ferra\u00f9","year":"2018","unstructured":"Ferra\u00f9 F, Albani A, Ciresi A, Giordano C, Cannav\u00f2 S (2018) Diabetes secondary to acromegaly: physiopathology, clinical features and effects of treatment. Front Endocrinol 9:358","journal-title":"Front Endocrinol"},{"issue":"5","key":"1185_CR7","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1530\/EJE-16-1064","volume":"176","author":"L Maione","year":"2017","unstructured":"Maione L, Brue T, Beckers A, Delemer B, Petrossians P, Borson-Chazot F et al (2017) Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry. Eur J Endocrinol 176(5):645\u2013655","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1185_CR8","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s11102-011-0335-y","volume":"15","author":"Y Tutuncu","year":"2012","unstructured":"Tutuncu Y, Berker D, Isik S, Ozuguz U, Akbaba G, Kucukler FK et al (2012) Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly. Pituitary 15(3):398\u2013404","journal-title":"Pituitary"},{"issue":"4","key":"1185_CR9","doi-asserted-by":"publisher","first-page":"454","DOI":"10.4158\/EP-2019-0528","volume":"26","author":"N Qiao","year":"2020","unstructured":"Qiao N, He M, Shen M, Zhang Q, Zhang Z, Shou X et al (2020) Comparative efficacy of medical treatment for acromegaly: a systematic review and network meta-analysis of integrated randomized trials and observational studies. Endocr Pract 26(4):454\u2013462","journal-title":"Endocr Pract"},{"issue":"5","key":"1185_CR10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1530\/eje.0.1460707","volume":"146","author":"C Bruns","year":"2002","unstructured":"Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G (2002) SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146(5):707\u2013716","journal-title":"Eur J Endocrinol"},{"key":"1185_CR11","first-page":"227","volume":"10","author":"D Cuevas-Ramos","year":"2016","unstructured":"Cuevas-Ramos D, Fleseriu M (2016) Pasireotide: a novel treatment for patients with acromegaly. Drug Des Devel Ther 10:227\u2013239","journal-title":"Drug Des Devel Ther"},{"issue":"11","key":"1185_CR12","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","volume":"2","author":"MR Gadelha","year":"2014","unstructured":"Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M et al (2014) Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2(11):875\u2013884","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"1185_CR13","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2337\/dci18-0033","volume":"41","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, D\u2019Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G et al (2018) Management of hyperglycemia in Type 2 diabetes, 2018. A consensus report by the american diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care 41(12):2669\u20132701","journal-title":"Diabetes Care"},{"issue":"6","key":"1185_CR14","doi-asserted-by":"publisher","first-page":"e2247","DOI":"10.1210\/clinem\/dgaa040","volume":"105","author":"P Marques","year":"2020","unstructured":"Marques P, Caimari F, Hern\u00e1ndez-Ram\u00edrez LC, Collier D, Iacovazzo D, Ronaldson A et al (2020) Significant benefits of AIP testing and clinical screening in familial isolated and young-onset pituitary tumors. J Clin Endocrinol Metab 105(6):e2247\u2013e2260","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1185_CR15","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933\u20133951","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1185_CR16","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00431-010-1329-x","volume":"170","author":"Z Ku\u0142aga","year":"2011","unstructured":"Ku\u0142aga Z, Litwin M, Tkaczyk M, Palczewska I, Zaj\u0105czkowska M, Zwoli\u0144ska D et al (2011) Polish 2010 growth references for school-aged children and adolescents. Eur J Pediatr 170(5):599\u2013609","journal-title":"Eur J Pediatr"},{"issue":"6","key":"1185_CR17","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1530\/EJE-19-0762","volume":"182","author":"A Colao","year":"2020","unstructured":"Colao A, Bronstein MD, Brue T, De Marinis L, Fleseriu M, Guitelman M et al (2020) Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study. Eur J Endocrinol 182(6):583","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1185_CR18","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s11102-013-0483-3","volume":"17","author":"A Colao","year":"2014","unstructured":"Colao A, De Block C, Gaztambide MS, Kumar S, Seufert J, Casanueva FF (2014) Managing hyperglycemia in patients with Cushing\u2019s disease treated with pasireotide: medical expert recommendations. Pituitary 17(2):180\u2013186","journal-title":"Pituitary"},{"key":"1185_CR19","doi-asserted-by":"publisher","first-page":"931","DOI":"10.3389\/fendo.2019.00931","volume":"10","author":"M Gadelha","year":"2019","unstructured":"Gadelha M, Bex M, Colao A, Pedroza Garc\u00eda EM, Poiana C, Jimenez-Sanchez M et al (2019) Evaluation of the efficacy and safety of switching to pasireotide in patients with acromegaly inadequately controlled with first-generation somatostatin analogs. Front Endocrinol 10:931","journal-title":"Front Endocrinol"},{"issue":"7","key":"1185_CR20","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1507\/endocrj.EJ16-0624","volume":"64","author":"S Tahara","year":"2017","unstructured":"Tahara S, Murakami M, Kaneko T, Shimatsu A (2017) Efficacy and safety of long-acting pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study. Endocr J 64(7):735\u2013747","journal-title":"Endocr J"},{"issue":"1","key":"1185_CR21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s12020-016-0895-8","volume":"53","author":"HA Schmid","year":"2016","unstructured":"Schmid HA, Brue T, Colao A, Gadelha MR, Shimon I, Kapur K et al (2016) Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. Endocrine 53(1):210\u2013219","journal-title":"Endocrine"},{"issue":"2","key":"1185_CR22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1210\/er.2010-0002","volume":"32","author":"A Colao","year":"2011","unstructured":"Colao A, Auriemma RS, Lombardi G, Pivonello R (2011) Resistance to somatostatin analogs in acromegaly. Endocr Rev 32(2):247\u2013271","journal-title":"Endocr Rev"},{"key":"1185_CR23","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2147\/TCRM.S183360","volume":"16","author":"G Corica","year":"2020","unstructured":"Corica G, Ceraudo M, Campana C, Nista F, Cocchiara F, Boschetti M et al (2020) Octreotide-resistant acromegaly: challenges and solutions. Ther Clin Risk Manag 16:379\u2013391","journal-title":"Ther Clin Risk Manag"},{"issue":"8","key":"1185_CR24","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1210\/jc.2005-2661","volume":"91","author":"SO Akintoye","year":"2006","unstructured":"Akintoye SO, Kelly MH, Brillante B, Cherman N, Turner S, Butman JA et al (2006) Pegvisomant for the treatment of gsp-mediated growth hormone excess in patients with McCune-Albright syndrome. J Clin Endocrinol Metab 91(8):2960\u20132966","journal-title":"J Clin Endocrinol Metab"},{"issue":"OC510","key":"1185_CR25","first-page":"2015","volume":"39","author":"EID Coxson","year":"2015","unstructured":"Coxson EID, Bunce B et al (2015) Pegvisomant treatment for X-linked acrogigantism syndrome. Endocr Abstr 39(OC510):2015","journal-title":"Endocr Abstr"},{"issue":"1","key":"1185_CR26","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13023-019-1102-9","volume":"14","author":"MK Javaid","year":"2019","unstructured":"Javaid MK, Boyce A, Appelman-Dijkstra N, Ong J, Defabianis P, Offiah A et al (2019) Best practice management guidelines for fibrous dysplasia\/McCune-Albright syndrome: a consensus statement from the FD\/MAS international consortium. Orphanet J Rare Dis 14(1):139","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"1185_CR27","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s11102-016-0732-3","volume":"19","author":"R Mangupli","year":"2016","unstructured":"Mangupli R, Rostomyan L, Castermans E, Caberg JH, Camperos P, Krivoy J et al (2016) Combined treatment with octreotide LAR and pegvisomant in patients with pituitary gigantism: clinical evaluation and genetic screening. Pituitary 19(5):507\u2013514","journal-title":"Pituitary"},{"issue":"4","key":"1185_CR28","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1530\/EC-19-0004","volume":"8","author":"AF Daly","year":"2019","unstructured":"Daly AF, Rostomyan L, Betea D, Bonneville JF, Villa C, Pellegata NS et al (2019) AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients. Endocr Connect 8(4):367\u2013377","journal-title":"Endocr Connect"},{"issue":"4","key":"1185_CR29","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1530\/EC-19-0027","volume":"8","author":"AF Daly","year":"2019","unstructured":"Daly AF, Cano DA, Venegas-Moreno E, Petrossians P, Dios E, Castermans E et al (2019) AIP and MEN1 mutations and AIP immunohistochemistry in pituitary adenomas in a tertiary referral center. Endocr Connect 8(4):338\u2013348","journal-title":"Endocr Connect"},{"issue":"6","key":"1185_CR30","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1210\/jc.2018-01979","volume":"104","author":"EC Coopmans","year":"2019","unstructured":"Coopmans EC, Muhammad A, van der Lely AJ, Janssen J, Neggers S (2019) How to position pasireotide LAR treatment in acromegaly. J Clin Endocrinol Metab 104(6):1978\u20131988","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1185_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ecl.2014.10.003","volume":"44","author":"RK Junnila","year":"2015","unstructured":"Junnila RK, Strasburger CJ, Bidlingmaier M (2015) Pitfalls of insulin-like growth factor-i and growth hormone assays. Endocrinol Metab Clin North Am 44(1):27\u201334","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"8","key":"1185_CR32","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1373\/clinchem.2008.105726","volume":"54","author":"TV Nguyen","year":"2008","unstructured":"Nguyen TV, Nelson AE, Howe CJ, Seibel MJ, Baxter RC, Handelsman DJ et al (2008) Within-subject variability and analytic imprecision of insulinlike growth factor axis and collagen markers: implications for clinical diagnosis and doping tests. Clin Chem 54(8):1268\u20131276","journal-title":"Clin Chem"},{"issue":"EP716","key":"1185_CR33","first-page":"2015","volume":"37","author":"FHP Gabalec","year":"2015","unstructured":"Gabalec FHP, Pacovsky J, Cap J (2015) Escape from response to long-term pasireotide treatment in recurrent cushing\u2019s disease. Endocr Abstr 37(EP716):2015","journal-title":"Endocr Abstr"},{"issue":"6","key":"1185_CR34","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s11102-016-0755-9","volume":"19","author":"Y Greenman","year":"2016","unstructured":"Greenman Y, Stern N (2016) Paradoxical and atypical responses to pasireotide in aggressive ACTH-secreting pituitary tumors. Pituitary 19(6):605\u2013611","journal-title":"Pituitary"},{"issue":"3","key":"1185_CR35","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1210\/jc.2018-02080","volume":"104","author":"M Theodoropoulou","year":"2019","unstructured":"Theodoropoulou M, Reincke M (2019) Tumor-directed therapeutic targets in cushing disease. J Clin Endocrinol Metab 104(3):925\u2013933","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1185_CR36","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1210\/jc.2013-1771","volume":"98","author":"RR Henry","year":"2013","unstructured":"Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S (2013) Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 98(8):3446\u20133453","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1185_CR37","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1007\/s11102-016-0734-1","volume":"19","author":"JM Silverstein","year":"2016","unstructured":"Silverstein JM (2016) Hyperglycemia induced by pasireotide in patients with Cushing\u2019s disease or acromegaly. Pituitary 19(5):536\u2013543","journal-title":"Pituitary"},{"issue":"10","key":"1185_CR38","doi-asserted-by":"publisher","first-page":"813","DOI":"10.7326\/M20-2470","volume":"173","author":"K Doyle-Delgado","year":"2020","unstructured":"Doyle-Delgado K, Chamberlain JJ, Shubrook JH, Skolnik N, Trujillo J (2020) Pharmacologic approaches to glycemic treatment of type 2 diabetes: synopsis of the 2020 American diabetes association\u2019s standards of medical care in diabetes clinical guideline. Ann Intern Med 173(10):813\u2013821","journal-title":"Ann Intern Med"},{"issue":"3","key":"1185_CR39","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s11102-014-0585-6","volume":"18","author":"M Sheppard","year":"2015","unstructured":"Sheppard M, Bronstein MD, Freda P, Serri O, De Marinis L, Naves L et al (2015) Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter Phase III study. Pituitary 18(3):385\u2013394","journal-title":"Pituitary"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-021-01185-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-021-01185-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-021-01185-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T10:49:18Z","timestamp":1644230958000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-021-01185-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,8]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1185"],"URL":"https:\/\/doi.org\/10.1007\/s11102-021-01185-w","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,8]]},"assertion":[{"value":"26 August 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}